SPIMACO inaugurates oncology, high-potent drug plant

Logo of Saudi Pharmaceutical Industries and Medical Appliances Corp. (SPIMACO) 

Saudi Pharmaceutical Industries and Medical Appliances Corp. (SPIMACO) inaugurated its oncology and high potent drugs plant, worth SAR 272 million.

In a statement to Tadawul today, July 27, SPIMACO said the plant boasts an annual production capacity exceeding 275 million therapeutic units.

For more news and details on the projects

Incorporating the latest technologies, the new facility adopts the highest international standards in pharmaceutical manufacturing, ensuring operational efficiency, personnel safety, and environmental sustainability.

As all technical, regulatory, and operational requirements were completed, the plant will produce the first commercial batches this month.

SPIMACO confirmed that the project is proceeding on track, expecting the relevant financial impact to start showing in Q4 2025.

This milestone reaffirms SPIMACO’s unwavering commitment to enhancing local pharmaceutical content by offering a wide range of specialized, high-quality medical products that meet the needs of both local and regional markets.

In November 2022, SPIMACO contracted for a new plant for the manfacturing of hazardous drugs, in partnership with global pharmaceutical firm AstraZeneca, at a total cost of SAR 272 million, Argaam earlier reported.